MAIA Biotechnology provides update on THIO-101 trial

MAIA Biotechnology announced treatment updates from its Phase 2 clinical trial, THIO-101, evaluating THIO sequenced with the immune checkpoint inhibitor, or CPI, cemiplimab in patients with advanced non-small cell lung cancer, or NSCLC, who failed two or more standard-of-care therapy regimens. The trial’s therapeutic regimen is cycled every three weeks, with THIO 180mg administered in 60mg incremental doses on days 1, 2 and 3, followed by immune activation on day 4, and cemiplimab 350mg administered on day 5. As of the latest clinical cutoff date, June 12: six patients remain on treatment following at least 12 months of therapy. Treatment with THIO followed by cemiplimab has been well tolerated throughout the trial, with much lower toxicity compared to standard-of care treatments. Continuing treatment past 12 months demonstrates safety, efficacy and ongoing benefit from MAIA‘s novel telomere targeting NSCLC therapy.